(Q34686445)

3 August 2017

1 reference

title

Endometrial safety of hormone replacement therapy: review of literature (English)

1 reference

Hormone Replacement Therapy

3 August 2017

1 reference

1

Toon Van Gorp

0 references

Patrick Neven

series ordinal

2

object named as

Patrick Neven

1 reference

3 August 2017

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

42

1 reference

3 August 2017

93-104

1 reference

3 August 2017

2

1 reference

OVARIAN SECRETION AND TUMOR INCIDENCE

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

UTERINE ADENOMATA IN THE RABBIT : III. SUSCEPTIBILITY AS A FUNCTION OF CONSTITUTIONAL FACTORS.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Malignant lesions of the uterus associated with estrogen-producing ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The age distribution in female breast and genital cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Precursors of corpus carcinoma estrogens and adenomatous hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Clinical studies concerning the relationship of estrogens to the development of cancer of the corpus uteri

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Association of Exogenous Estrogen and Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Analysis of clinical susceptibility bias in case-control studies. Analysis as illustrated by the menopausal syndrome and the risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Pharmacokinetic and pharmacologic variation between different estrogen products

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Low-potency oestrogen and risk of endometrial cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Review of the endometrial safety during intravaginal treatment with estriol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated Estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Endometrial hyperplasia in women on cyclic or continuous estrogen regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Exposure to phenoxy herbicides and the risk of spontaneous abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Hormone replacement therapy and endometrial cancer: are current regimens safe?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Changes in the withdrawal bleeding pattern and endometrial histology during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Estrogen-progestin replacement therapy and endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Endometrial response in estrogen replacement therapy quarterly combined with a progestogen

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

1 reference

7 January 2021

The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Compliance with hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Compliance with hormonal replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Steroids and the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

1 reference

7 January 2021

The endometrial status of women on long-term continuous combined hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Continuous hormone replacement therapy for menopause combining nomegestrol acetate and gel, patch, or oral estrogen: a comparison of amenorrhea rates

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Effect of the levonorgestrel-releasing intrauterine system on the uterine artery pulsatility index in postmenopausal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The incidence of vaginal bleeding with tibolone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow doppler: study in different phases of sequential therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Monitoring of oestrogen replacement therapy by vaginosonography of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

The role of GnRH agonists plus add-back therapy in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Estrogen replacement therapy following treatment for stage I endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Estrogen replacement in surgical stage I and II endometrial cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

Estrogen replacement therapy in endometrial cancer patients: a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900031-2

7 January 2021

10.1016/S0378-5122(02)00031-2

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12065168